|
|
|
|
|
|
|
Can-Fite Biopharma Ltd (CANF)
|
|
1.38 0.01 (0.73%)
|
04-25 13:36
|
|
Open:
|
1.36
|
Pre. Close:
|
1.37
|
|
High:
|
1.38
|
Low:
|
1.28
|
|
Volume:
|
70,885
|
Market Cap:
|
29M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
1.401 - 1.411
|
1.411 - 1.419
|
|
Low:
|
1.322 - 1.332
|
1.332 - 1.34
|
|
Close:
|
1.357 - 1.372
|
1.372 - 1.385
|
|
|
|
Technical analysis (as of: 2018-04-25 1:49:19 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a SELL today, downgraded from higher rating. This stock seems to be ready for a new bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.
|
|
Target:
|
Six months: 1.65 One year: 1.75
|
|
Support:
|
Support1: 1.28 Support2: 1.06
|
|
Resistance:
|
Resistance1:
1.42 Resistance2: 1.50
|
|
Pivot:
|
1.41
|
|
Moving Averages:
|
MA(5): 1.37 MA(20): 1.42
MA(100): 1.68 MA(250): 1.69
|
|
MACD:
|
MACD(12,26):
-0.06 Signal(12,26,9): -0.07 
|
|
%K %D:
|
%K(14,3): 18.40 %D(3): 17.64
|
|
RSI:
|
RSI(14): 31.57
|
|
52-Week:
|
High: 2.75
Low: 1.24 Change(%): -30.1
|
|
Average Vol(K):
|
3-Month: 9136
10-Days 3432
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.CANF has closed below the lower band by 3.0%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 69.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to CANF's normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
|
|
|
Headline News
|
|
2018-04-25T09:00:34-04:00
AbbVie files U.S. marketing application for plaque psoriasis med risankizumab
2018-04-25T07:00:00-04:00
Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research'
2018-04-24T13:09:52-04:00
Adenosine A3 Receptor Agonist-Namodenoson And NASH: Can-Fite Biopharma Is Fighting The Good Fight
2018-04-09T07:00:00-04:00
Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)
2018-03-28T07:00:00-04:00
Can-Fite to Present at the MicroCap Conference
2018-03-23T09:23:21-04:00
Can-Fite Biopharma net loss improves in FY 2017
2018-03-23T07:21:45-04:00
Can-Fite Biopharma reports FY results
2018-03-23T07:00:00-04:00
Can-Fite Reports 2017 Financial Results & Provides Clinical Update
|
|
|
Financial Analysis
|
|
Growth
|
NA
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
NA
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
NA
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
